產(chǎn)品名稱(chēng) N106
產(chǎn)品貨號(hào) Axon 2565 CAS [862974-25-2] MF C17H14N4O3SMW 354.38 Purity: 99% Soluble in DMSO Description First-in-class small-molecule activator targeting E1 ligase mediated SERCA2a SUMOylation. N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure. KEYWORDS:?N106 | supplier | E1 ligase activator | N-106 | CAS [862974-25-2] | Ubiquitin | Ubiquitin Ligase (E1) | Activator | small ubiquitin-like modifier type 1 | SUMO-1 | SERCA2a | SUMOylation | heart failure | cardiomyocyte | cardiac | sarcoplasmic reticulum | calcium | ATPase
產(chǎn)品價(jià)格 現(xiàn)貨詢價(jià)，電話：010-67529703
產(chǎn)品規(guī)格
產(chǎn)品品牌 axonmedchem
產(chǎn)品概述
產(chǎn)品詳情

N106

Based on 5 reference(s) in Google Scholar 8 10 5

Axon 2565

CAS [862974-25-2]

MF C17H14N4O3S
MW 354.38

  • Purity: 99%
  • Soluble in DMSO

N106

Description

First-in-class small-molecule activator targeting E1 ligase mediated SERCA2a SUMOylation. N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure.

KEYWORDS:?N106 | supplier | E1 ligase activator | N-106 | CAS [862974-25-2] | Ubiquitin | Ubiquitin Ligase (E1) | Activator | small ubiquitin-like modifier type 1 | SUMO-1 | SERCA2a | SUMOylation | heart failure | cardiomyocyte | cardiac | sarcoplasmic reticulum | calcium | ATPase
產(chǎn)品資料